Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. INM
stocks logo

INM

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2024Q4
1.78M
-22.48%
--
--
Estimates Revision
Stock Price
Go Down
down Image
-36.49%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for InMed Pharmaceuticals Inc (INM.O) is 0.00, compared to its 5-year average forward P/E of -0.82. For a more detailed relative valuation and DCF analysis to assess InMed Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.82
Current PE
0.00
Overvalued PE
0.31
Undervalued PE
-1.95

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.32
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.48
Undervalued EV/EBITDA
-1.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.56
Current PS
0.00
Overvalued PS
7.80
Undervalued PS
-2.67
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

INM News & Events

Events Timeline

(ET)
2025-11-18
09:40:46
InMed Reports Completion of Pharmacokinetic Studies for Alzheimer's Treatment Candidate
select
2025-09-23 (ET)
2025-09-23
08:40:41
InMed Pharmaceuticals announces FY25 EPS of $8.36 compared to $20.14 from the previous year.
select
2025-06-25 (ET)
2025-06-25
08:13:17
InMed Pharmaceuticals announces $5M private placement
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-21Benzinga
Intuit Shares Rise: 20 Stocks Making Moves in Premarket Trading

  • Intuit's Financial Performance: Intuit Inc. reported better-than-expected first-quarter results, with revenue of approximately $3.89 billion and adjusted earnings of $3.34 per share, leading to a 3.2% increase in share price during pre-market trading.

  • Second-Quarter Expectations: The company anticipates second-quarter revenue growth of 14% to 15% and adjusted earnings between $3.63 and $3.68 per share, which is below analyst estimates.

  • Pre-Market Stock Movements: Several stocks saw significant pre-market trading movements, including Nuvve Holding Corp, which surged 49.4%, and Enviri Corp, which gained 31.5% after announcing a major sale.

  • Declines in Other Stocks: Conversely, Pasithea Therapeutics Corp experienced a notable decline of 25.3% following the release of interim trial data, alongside other stocks like Safe & Green Holdings Corp and VisionSys AI Inc, which also saw significant drops.

[object Object]
Preview
2.0
11-20Benzinga
Nvidia Shares Rise Over 5%; Check Out 20 Stocks Making Moves in Premarket Trading

  • NVIDIA's Strong Performance: NVIDIA Corp's shares rose 5.2% in pre-market trading after reporting a 62% year-over-year revenue increase to $57.0 billion for Q3, surpassing expectations with a strong revenue forecast for the current quarter.

  • Notable Gainers: Several stocks saw significant pre-market gains, including Sonder Holdings Inc (+138.8%), Inspire Veterinary Partners Inc (+60.3%), and Cerence Inc (+29.2%), following positive financial results or forecasts.

  • Major Losers: WeShop Holdings Limited experienced a sharp decline of 38.8% in pre-market trading after a previous surge, while other notable losers included Brera Holdings PLC (-35.5%) and Meihua International Medical Tech Co Ltd (-23.8%).

  • Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with some companies reporting better-than-expected financial results while others faced significant declines.

[object Object]
Preview
2.0
11-20Benzinga
What Factors Contributed to InMed's (INM) 22% Rise in After-Hours Trading?

  • Stock Performance: InMed Pharmaceuticals Inc. shares rose 21.98% in after-hours trading to $1.50, despite a 15.75% drop during the regular session, closing at $1.23.

  • Research Milestone: The company successfully completed pharmacokinetic studies for its Alzheimer’s candidate INM-901 in large animal models, demonstrating strong bioavailability and therapeutic exposure.

  • Regulatory Plans: InMed is preparing for Investigational New Drug (IND) submission by conducting dose-ranging studies and a pre-IND meeting with the FDA, alongside additional development for production scaling.

  • Financial Overview: As of September 30, InMed reported $9.3 million in cash, sufficient to fund operations into Q4 2026, although its stock has declined 74.38% this year, with a market cap of $3.45 million.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is InMed Pharmaceuticals Inc (INM) stock price today?

The current price of INM is 1.34 USD — it has increased 0 % in the last trading day.

arrow icon

What is InMed Pharmaceuticals Inc (INM)'s business?

InMed Pharmaceuticals Inc. is a pharmaceutical company. The Company develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.

arrow icon

What is the price predicton of INM Stock?

Wall Street analysts forecast INM stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for INM is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is InMed Pharmaceuticals Inc (INM)'s revenue for the last quarter?

InMed Pharmaceuticals Inc revenue for the last quarter amounts to 1.12M USD, decreased -11.43 % YoY.

arrow icon

What is InMed Pharmaceuticals Inc (INM)'s earnings per share (EPS) for the last quarter?

InMed Pharmaceuticals Inc. EPS for the last quarter amounts to -0.44 USD, decreased -99.19 % YoY.

arrow icon

What changes have occurred in the market's expectations for InMed Pharmaceuticals Inc (INM)'s fundamentals?

The market is revising No Change the revenue expectations for INM for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -36.49%.
arrow icon

How many employees does InMed Pharmaceuticals Inc (INM). have?

InMed Pharmaceuticals Inc (INM) has 13 emplpoyees as of December 05 2025.

arrow icon

What is InMed Pharmaceuticals Inc (INM) market cap?

Today INM has the market capitalization of 3.76M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free